JURA BioJURA Bio
JURA Bio
JURA.Bio is a pioneering biotechnology company that combines AI and synthetic biology to develop next-generation genomic medicines and immune-based therapies. The company focuses on the discovery and development of novel TCR (T-cell receptor) therapies targeting the TCR-epitope-HLA synapse, a critical biological target for personalized medicine and immunotherapy.
Key features and capabilities include:
  • End-to-End Discovery Platform: JURA.Bio’s platform integrates generative machine learning and synthetic biology to design, build, and test new therapeutic molecules at scale.
  • Large-Scale TCR Library: The company has developed a library of over 100 billion human TCR candidates, enabling the discovery of antigen-specific TCRs for various diseases, including prostate cancer and other neoantigen targets.
  • Predictive Modeling: JURA.Bio uses advanced machine learning models to predict complex molecular interactions, accelerating the development of safe and effective therapies.
  • Applications in Oncology and Autoimmunity: The platform is designed to address challenging targets in cancer and autoimmune diseases, with a focus on developing therapies that are both effective and safe.
JURA.Bio’s innovative approach is ideal for applications in personalized medicine, cancer immunotherapy, and the development of novel genomic medicines.

数据统计

相关导航

暂无评论

none
暂无评论...